Brief: Cambridge Cognition Says Monument Therapeutics Achieves Positive Phase I Results For Novel Schizophrenia Treatment
24/06/2025 07:44
June 24 (Reuters) - Cambridge Cognition Holdings PLC COGC.L: CAMBRIDGE COGNITION: MONUMENT THERAPEUTICS ACHIEVES POSITIVE PHASE I RESULTS FOR NOVEL SCHIZOPHRENIA TREATMENT Source text: ID:nRSX0554Oa Further company coverage: COGC.L ((( Reuters.Briefs@thomsonreuters.com );))
Recent news on Cambridge Cognition Holdings
See all newsBrief: Cambridge Cognition Announces Retail Offer Of New Ordinary Shares At 35 Pence/Share
Cambridge Cognition - Retail Offer
Cambridge Cognition - Result of Placing & Posting of Circular
Brief: Cambridge Cognition To Raise Minimum £2.5 Mln Via Placing & Subscription At 35p Per Share
Cambridge Cognition - Proposed Equity Fundraising and Retail Offer